| Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS HJD O’Brien WA, Hartigan PH, Martin D, Esinhart J, Hill A, Benoit S, Rubin M ... New England Journal of Medicine 334, 426-31, 1996 | 934 | 1996 |
| PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing F Li, R Goila-Gaur, K Salzwedel, NR Kilgore, M Reddick, C Matallana, ... Proceedings of the National Academy of Sciences 100 (23), 13555-13560, 2003 | 539 | 2003 |
| Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid … PF Smith, A Ogundele, A Forrest, J Wilton, K Salzwedel, J Doto, ... Antimicrobial agents and chemotherapy 51 (10), 3574-3581, 2007 | 251 | 2007 |
| Pharmacokinetics of lamivudine administered alone and with trimethoprim‐sulfamethoxazole KHP Moore, GJ Yuen, RH Raasch, JJ Eron, D Martin, PK Mydlow, ... Clinical Pharmacology & Therapeutics 59 (5), 550-558, 1996 | 147 | 1996 |
| Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection DE Martin, K Salzwedel, GP Allaway Antiviral Chemistry and Chemotherapy 19 (3), 107-113, 2008 | 112 | 2008 |
| Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction JQ Tran, SJ Kovacs, TS McIntosh, HM Davis, DE Martin The Journal of Clinical Pharmacology 39 (5), 487-494, 1999 | 107 | 1999 |
| Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers DJ Kazierad, DE Martin, RA Blum, DM Tenero, B Ilson, SC Boike, ... Clinical Pharmacology & Therapeutics 62 (4), 417-425, 1997 | 105 | 1997 |
| Maturation inhibitors: a new therapeutic class targets the virus structure. K Salzwedel, DE Martin, M Sakalian AIDS reviews 9 (3), 162-172, 2007 | 99 | 2007 |
| Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1–infected, treatment-experienced, CCR5 antagonist–naive subjects J Lalezari, J Gathe, C Brinson, M Thompson, C Cohen, E Dejesus, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 57 (2), 118-125, 2011 | 88 | 2011 |
| Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers DE Martin, R Blum, J Wilton, J Doto, H Galbraith, GL Burgess, PC Smith, ... Antimicrobial Agents and Chemotherapy 51 (9), 3063-3066, 2007 | 86 | 2007 |
| Determinants of activity of the HIV-1 maturation inhibitor PA-457 F Li, D Zoumplis, C Matallana, NR Kilgore, M Reddick, AS Yunus, ... Virology 356 (1-2), 217-224, 2006 | 81 | 2006 |
| Urinary excretion of 6β‐hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations SJ Kovacs, DE Martin, DE Everitt, SD Patterson, DK Jorkasky Clinical Pharmacology & Therapeutics 63 (6), 617-622, 1998 | 78 | 1998 |
| The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV D Yu, CT Wild, DE Martin, SL Morris-Natschke, CH Chen, GP Allaway, ... Expert opinion on investigational drugs 14 (6), 681-693, 2005 | 66 | 2005 |
| Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food D Tenero, D Martin, B Ilson, J Jushchyshyn, S Boike, D Lundberg, ... Biopharmaceutics & drug disposition 19 (6), 351-356, 1998 | 61 | 1998 |
| Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients JF Marier, MM Trinh, LH Pheng, SM Palleja, DE Martin Antimicrobial agents and chemotherapy 55 (6), 2768-2774, 2011 | 57 | 2011 |
| Alkyl amine bevirimat derivatives are potent and broadly active HIV-1 maturation inhibitors E Urano, SD Ablan, R Mandt, GT Pauly, DM Sigano, JP Schneider, ... Antimicrobial agents and chemotherapy 60 (1), 190-197, 2016 | 53 | 2016 |
| Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice CA Stoddart, P Joshi, B Sloan, JC Bare, PC Smith, GP Allaway, CT Wild, ... PLoS One 2 (11), e1251, 2007 | 53 | 2007 |
| Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers DE Martin, R Blum, J Doto, H Galbraith, C Ballow Clinical pharmacokinetics 46, 589-598, 2007 | 53 | 2007 |
| HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457) S McCallister, J Lalezari, G Richmond, M Thompson, R Harrigan, D Martin, ... Antivir Ther 13 (Suppl 3), A10, 2008 | 52 | 2008 |
| Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment DE Martin, MC Chapelsky, B Ilson, D Tenero, SC Boike, N Zariffa, ... The Journal of Clinical Pharmacology 38 (2), 129-137, 1998 | 50 | 1998 |
